172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)
Title:
172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC)
Author:
Singer, C.F. Egle, D. Greil, R. Öhler, L. Petru, E. Suppan, C. Marhold, M. Pfeiler, G. Brunner, C. Tinchon, C. Halper, S. Galid, A. Pluschnig, U. Haslbauer, F. Hubalek, M. Redl, A. Flatschacher, J. Hennebelle, M. Mraz, B. Bartsch, R.